AI-generated analysis. Always verify with the original filing.
On March 11, 2026, Lineage Cell Therapeutics, Inc. filed a prospectus with the SEC. The filing includes Exhibit 5.1, the opinion of Sheppard, Mullin, Richter & Hampton LLP, and Exhibit 23.1, their consent.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On March 11, 2026, Lineage Cell Therapeutics, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Sheppard, Mullin, Richter & Hampton LLP 23.1 Consent of Sheppard, Mullin